{"id":9612,"date":"2026-08-24T11:58:26","date_gmt":"2026-08-24T08:28:26","guid":{"rendered":"https:\/\/pharmex.me\/en\/?p=9612"},"modified":"2026-08-24T11:58:26","modified_gmt":"2026-08-24T08:28:26","slug":"pharmex-2026-from-product-showcase-to-a-platform-for-knowledge-technology-investment-and-solutions","status":"publish","type":"post","link":"https:\/\/pharmex.me\/en\/2026\/08\/24\/pharmex-2026-from-product-showcase-to-a-platform-for-knowledge-technology-investment-and-solutions\/","title":{"rendered":"Pharmex 2026: From Product Showcase to a Platform for Knowledge, Technology, Investment, and Solutions"},"content":{"rendered":"<p><strong>An article by Dr. Iman Iranmanesh, Scientific Secretary of Pharmex 2026 and Scientific Advisor to the Syndicate of Pharmaceutical, Chemical, and Pharmaceutical Packaging Manufacturers<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>The pharmaceutical industry should be analyzed in connection with the broader <strong>political, economic, social, technological, legal, and environmental (PESTLE)<\/strong> landscape. What happens in pharmaceutical factories, laboratories, supply chains, and markets is largely a reflection of the conditions shaped at the country\u2019s macroeconomic level.<\/p>\n<p>Exchange rates, inflation, financing costs, access to capital, trade policies, international restrictions, energy availability, consumers\u2019 purchasing power, and the government\u2019s budgetary and foreign exchange policies are all variables within the <strong>macro environment<\/strong> that directly influence <strong>micro-level decisions<\/strong> made by pharmaceutical companies\u2014from selecting raw materials and technologies to investment, production costs, product development, employment, and even the ability to enter export markets.<\/p>\n<p>Therefore, some of the pharmaceutical industry\u2019s challenges cannot be addressed solely through industry-level solutions. Just as macroeconomic policies affect the pharmaceutical industry, the development of the pharmaceutical sector can also influence macroeconomic variables, including specialized employment, foreign currency generation, exports, technological development, and reduced dependence on foreign currency.<\/p>\n<p><strong>Pharmex 2026 can serve as a point of connection between these two levels<\/strong>\u2014a place where macroeconomic issues are translated into the language of industry, while industry challenges and priorities are reflected in the language of policymaking.<\/p>\n<h3>\u00a0Moving from an Exhibition to an Industry Platform<\/h3>\n<p>The experience of major international exhibitions also demonstrates that next-generation exhibitions are no longer simply collections of booths. <strong>CPHI<\/strong>, for example, now connects the entire pharmaceutical value chain\u2014from APIs and excipients to manufacturing, packaging, technology, and services\u2014while offering business matching, conferences, and specialized content alongside the exhibition.<\/p>\n<p>At <strong>ACHEMA<\/strong>, the exhibition is similarly integrated with a scientific congress and specialized programs covering areas ranging from AI and Digital Twins to automation, intelligent processes, and advanced manufacturing technologies. The event\u2019s <strong>Digital Hub<\/strong> is also designed as a space for showcasing, learning about, and networking around digital technologies.<\/p>\n<p><strong>This is the direction that can also be envisioned for Pharmex: moving from showcasing products to showcasing knowledge, technology, investment, and solutions.<\/strong><\/p>\n<p>In this context, <strong>Industry 4.0 and Industry 5.0 technologies<\/strong>, referred to as <strong>Pharma 4.0 and Pharma 5.0<\/strong> in the pharmaceutical sector, are particularly important. Artificial intelligence, Digital Twins, advanced automation, data-driven operations, predictive maintenance, robotics, flexible manufacturing, and connected systems are no longer merely technological topics. They are gradually becoming key determinants of productivity and industrial competitiveness.<\/p>\n<p><strong>Industry 5.0<\/strong> goes a step further by emphasizing not only intelligence and automation, but also <strong>human-centricity, sustainability, and resilience<\/strong>\u2014concepts that are particularly important for the future of Iran\u2019s pharmaceutical industry.<\/p>\n<p>From this perspective, <strong>Pharmex 2026 should provide a platform for simultaneous dialogue on economics, technology, and industry.<\/strong><\/p>\n<h3>\u00a0Workshops and Panels: From Education to an Industry Think Tank<\/h3>\n<p>For this reason, specialized workshops and panels at Pharmex should not be limited to educational purposes. These programs can evolve into <strong>industry think tanks<\/strong>\u2014spaces where policymakers, industry executives, investors, technology experts, universities, and knowledge-based companies can directly engage with the industry\u2019s real-world challenges.<\/p>\n<p>Potential topics could include:<\/p>\n<ul>\n<li>Macroeconomics and the future of the pharmaceutical industry<\/li>\n<li>Foreign exchange policy and industry financing<\/li>\n<li>Investment and new models of capital financing<\/li>\n<li>Industry 4.0 &amp; 5.0 in pharmaceutical manufacturing<\/li>\n<li>Artificial Intelligence and Digital Twins in R&amp;D and manufacturing<\/li>\n<li>The future of pharmaceutical raw materials and advanced manufacturing technologies<\/li>\n<li>Productivity, energy, and the economics of manufacturing<\/li>\n<li>Exports and regional competitiveness<\/li>\n<li>Digital transformation and the future of the pharmaceutical value chain<\/li>\n<li>Innovation policy and industry\u2013academia collaboration<\/li>\n<\/ul>\n<h3>\u00a0Pharmex: A Bridge Between Policymakers, Industry, Capital, and Technology<\/h3>\n<p>If <strong>Pharmex 2026<\/strong> can build bridges between policymakers and industry, capital and technology, academia and manufacturing, and the domestic and regional markets, it will go far beyond being merely an exhibition.<\/p>\n<p>The ultimate goal is to create something larger than an <strong>\u201cexhibition\u201d<\/strong>\u2014an <strong>Industry Platform<\/strong> where challenges are identified, knowledge is shared, technologies are introduced, capital is connected with opportunities, and dialogue is transformed into collaboration.<\/p>\n<p><strong>Iran\u2019s pharmaceutical industry needs such a platform now more than ever to overcome the challenges it faces today.<\/strong><\/p>\n<p>Pharmex 2026 can become a place where the pharmaceutical industry does not simply discuss its present, but also makes decisions about <strong>the economy, technology, and its position in the Iran of tomorrow.<\/strong><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>An article by Dr. Iman Iranmanesh, Scientific Secretary of Pharmex 2026 and Scientific Advisor to the Syndicate of Pharmaceutical, Chemical, and Pharmaceutical Packaging Manufacturers &nbsp; The pharmaceutical industry should be analyzed in connection with the broader political, economic, social, technological, legal, and environmental (PESTLE) landscape. What happens in pharmaceutical factories, laboratories, supply chains, and markets [&hellip;]<\/p>\n","protected":false},"author":2757,"featured_media":9613,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9612","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmex-news"],"_links":{"self":[{"href":"https:\/\/pharmex.me\/en\/wp-json\/wp\/v2\/posts\/9612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmex.me\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmex.me\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmex.me\/en\/wp-json\/wp\/v2\/users\/2757"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmex.me\/en\/wp-json\/wp\/v2\/comments?post=9612"}],"version-history":[{"count":1,"href":"https:\/\/pharmex.me\/en\/wp-json\/wp\/v2\/posts\/9612\/revisions"}],"predecessor-version":[{"id":9614,"href":"https:\/\/pharmex.me\/en\/wp-json\/wp\/v2\/posts\/9612\/revisions\/9614"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmex.me\/en\/wp-json\/wp\/v2\/media\/9613"}],"wp:attachment":[{"href":"https:\/\/pharmex.me\/en\/wp-json\/wp\/v2\/media?parent=9612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmex.me\/en\/wp-json\/wp\/v2\/categories?post=9612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmex.me\/en\/wp-json\/wp\/v2\/tags?post=9612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}